Singh Biotech LLP

02/10/2019

Dear Friends, We are Happy to share Our Founder Manoj Kumar Singh has been confirmed as a Nominee for The Campus Connect -REX Karmaveer Global Young Leaders Fellowship ( ) and Karmaveer Chakra Awards 2019 instituted by in partnership with the .

Keep Supporting And Blessing Me. Being A Hemophiliac It Is A Recognition For Our Potential To Bring A Change In Society And That We Can Do Anything. 🙏🙏

celebrates young from colleges globally, who make a difference in our society with their to be the change and REXChange mindsets by walking the path less trodden. The award to honour individual work done by people to "be the change" and/or walk off beat road or any field of work that inspires and brings in Growth mindset.
The Campus Connect REX - Ideas for Action

24/09/2019

Now Bye Bye To Lab Technicians..

An artificial intelligence-powered microscope able to detect tumor cells in histopathology slides holds promise for accelerating pathology workflows for cancer diagnosis

09/07/2019

Our founder gets featured as Rare Warrior And His Life Story In Brief... Lets All Get Inspired... Please Like and Share The Video
https://youtu.be/Cm6v57KqsZo

Humara Iss Episode Ke Rare Warrior Manoj Kumar Singh Hain. Wo Ek Rare Bleeding Disorder Hemophilia, Jise Royal Disease Bhi Kehte Hain Se Lad Rahe Hain. Hemop...

03/04/2019

Now Indian Universities Can Also Carry out Research On People.. But need to follow ICMR guidelines...

Drugs that have been approved in other some countries will no longer require trials in India.

01/02/2019

Lilly price break reverses NICE’s 'No' ruling on breast cancer drug Verzenio..Read On...http://bit.ly/2Doo7U9

#

England’s drug-cost watchdogs initially told Eli Lilly that its CDK 4/6 inhibitor to treat breast cancer, Verzenio, wasn't cost-effective compared to rivals from Pfizer and Novartis. So Lilly dished up a new price break—and now NICE is on board.

31/01/2019

Study: 1 in 4 antibiotic prescriptions likely inappropriate..Read On...http://bit.ly/2W5tBu4

A new study mapping ICD-10 diagnostic codes to antibiotic prescriptions found that almost a quarter of prescriptions were likely inappropriate for the conditions noted. And that’s probably a conservative estimate.

30/01/2019

Spectrum empties marketed portfolio worth $300M to deal-hungry Aurobindo..Read On...http://bit.ly/2sBr2mf

Buzz of a potential sale at Spectrum Pharma first emerged last June. As it turns out, the rare disease and cancer specialist is indeed pulling off a transaction—but only for its FDA-approved products. The buyer, Aurobindo, has been busy shopping lately.

29/01/2019

Apple, J&J to put the Apple Watch’s ECG through large-scale clinical testing..Read On...http://bit.ly/2W3X0oC

Apple and Johnson & Johnson are teaming up on a multiyear research study to see if the latest Apple Watch can help catch and diagnose elderly people with atrial fibrillation earlier and faster than before.

28/01/2019

Novartis allies with Oxford academics for big data R&D drive..Read On...http://bit.ly/2T5cRBg

Novartis has teamed up with the University of Oxford to use artificial intelligence to improve drug development. The collaboration will analyze MRI data from 35,000 multiple sclerosis patients and results from IL-17 inhibitor trials to better understand diseases important to Novartis’ prospects.

27/01/2019

Celgene strikes Obsidian deal to boost CAR-T options..Read On...http://bit.ly/2FzqpBW

Celgene is pushing ahead with its immuno-oncology dealmaking program while working toward its $74 billion takeout by Bristol-Myers Squibb. The big biotech ended the week by expanding its CAR-T toolkit via a deal with Obsidian Therapeutics and placing an $80 million bet on Kyn Therapeutics.